

Supplementary table 1. Molecular and clinical features of all patients included in the study. FTP: first time point; LTP: last time point; WBC, white blood cell; NA: no data available; MBL: monoclonal B-cells lymphocytosis; IGHV homology mutated = IGHV homology<98%; IGHV homology unmutated = IGHV homology>98%; Zap-70 positive: Zap-70>20%; Zap-70 negative: Zap-70<20%

Stable CLL																			
ID	Date of Diagnosis	FTP LTP	Date of First treatment	Date of last follow-up	Time frame (FTP-Date of diagnosis)	Time frame (LTP-FTP)	IGHV homology	Zap-70	WBC (x10 ⁹ /liter)	ALC (%from WBC)	CD19+/CD5+ (%from PBMC) clone	Binet/Rai Stage	Therapy need	Reference	CNV (pCR)	Mutational analysis	CNV (SNP genotyping)	Affy ID	
CLL478	May-99	Feb-03		Feb-10	1375.00	1022.00	mut	neg	19	NA	0	0	No	1	yes	yes	yes	A2317-16	
		Nov-05							18.7	47	0	0			yes	yes	yes	A2317-15	
		Jan-02		Jul-05	6195.00	441.00	mut	neg	21	82.4	NA	NA	No	1	yes	yes	yes	A2317-18	
CLL594	Dec-03	Nov-00					mut	neg	24	73.6	1	1	No	1	yes	yes	yes	A2317-17	
		Jan-02							11.3	74	1	1	No	1	yes	yes	yes	A2317-20	
		Apr-00		Mar-18	847.00	2931.00	mut	neg	12.7	76	2	2			yes	yes	yes	A2317-19	
CLL534	Jun-00	Oct-00		Nov-17	144.00	2432.00	mut	pos	10.2	41	0	0	No	1	yes	yes	yes	A2317-22	
		Jun-07							14	53	1	1			yes	yes	yes	A2317-21	
		Jan-02	Jul-12	Feb-18	1076.00	980.00	unmut	pos	17.3	63	1	1	Yes	1	yes	yes	yes	A2317-24	
CLL538	Jul-99	Feb-05					unmut	pos	9.9	65	2	2			yes	yes	yes	A2317-23	
		May-11		Jul-18	1988.00	741.00	mut	neg	48.2	87.3	72.3	BI	No	2	yes	yes	yes	A2317-01	
		May-13				1622.00			88	NA	94.1	BI	No	2	no	yes	yes	A2317-02	
LLC003	Dec-05	Oct-15					mut	neg	52	93.4	80.6	BI	No	2	yes	yes	yes	A2317-03	
		May-11		May-18	2755.00	660.00	mut	neg	50	86	83.1	BI	No	2	yes	yes	yes	A2317-04	
		Mar-13							26	91.9	88.1	BI	No	2	yes	yes	yes	A2317-05	
LLC008	Aug-08	Mar-11		Jun-17	1027.00	420.00	unmut	neg	15.7	65	50.9	AO	No	2	yes	yes	yes	A2317-06	
		Jul-12							16	72	60	AO			yes	yes	yes	A2317-06	
		Jul-12							16	72	60	AO			yes	yes	yes	A2317-06	
LLC012A	Oct-03	Feb-12		Dec-17	3065.00	1399.00	mut	neg	15	55	27.6	AO	No	2	yes	no	no		
		Dec-15							9	44	14.1	AO			yes	no	no		
		Dec-15							9	44	14.1	AO			yes	no	no		
LLC014	Sep-09	Jul-11		Aug-18	679.00	931.00	mut	neg	54	82.6	NA	All	Yes	2	yes	yes	yes		
		Mar-12	Sep-16						73	77.7	NA	All			yes	yes	yes		
		Oct-14							70	84	83.9	All			no	no	no		
LLC020	Mar-07	Oct-11		Apr-18	1885.00	826.00	unmut	neg	27	94	59.5	AO	No	2	yes	no	no		
		Jan-14							28	84.4	61.1	All			yes	no	no		
		Jan-16							29	85.5	53.9	AO	No	2	yes	no	yes	A3288-01	
LLC021	May-08	Oct-11		Feb-18	1258.00	1561.00	mut	neg	15	60	40.7	AO	No	2	yes	no	yes	A3288-01	
		Jan-16							29	85.5	53.9	AO			yes	no	yes	A3288-02	
		Jan-16							29	85.5	53.9	AO			yes	no	yes	A3288-02	
LLC031	Sep-09	Nov-11			819.00	1267.00	mut	neg	15	71	63.3	AO	No	2	yes	no	no		
		May-15							9	79.7	64.3	AO			yes	no	no		
		May-15							9	79.7	64.3	AO			yes	no	no		
LLC035	Oct-00	Dec-11		Sep-18	4084.00	532.00	mut	neg	34.3	84	84.8	BI	No	2	yes	yes	yes	A2317-27	
		Jan-12							23	85	78.9	BI			no	yes	yes	A2317-28	
		Jan-12							23	85	78.9	BI			no	yes	yes	A2317-28	
LLC039	Sep-05	Jan-12		May-18	2322.00	1519.00	mut	neg	68	89.7	95.5	BI	No	2	yes	no	no		
		Mar-16							107	90	89.5	BI			yes	no	no		
		Mar-16							107	90	89.5	BI			yes	no	no		
LLC052	Jan-10	Mar-12		Oct-17	795.00	378.00	mut	neg	29	88	66.2	All	No	2	no	yes	no		
		Mar-13							33	90	87.7	BI			no	yes	no		
		Mar-13							33	90	87.7	BI			no	yes	no		
LLC056	Aug-05	Mar-12		Nov-17	2416.00	1372.00	mut	neg	29	75.2	48.9	BI	No	2	yes	no	no		
		Dec-15							33	75	30.3	BI			yes	no	no		
		Dec-15							33	75	30.3	BI			yes	no	no		
LLC066	Nov-11	Sep-12		Jun-17	329.00	1178.00	mut	neg	12.8	62	31.8	AO	No	2	yes	no	yes	A3288-07	
		Dec-15							15.7	76.4	65.6	All			yes	no	yes	A3288-08	
		Dec-15							15.7	76.4	65.6	All			yes	no	yes	A3288-08	
LLC086	Mar-10	May-13		Apr-18	1184.00	966.00	unmut	neg	10	70.1	37.2	AO	No	2	yes	no	no		
		Jan-16							12	74.5	48.8	AO			yes	no	no		
		Jan-16		medan	1268.00	980.00													

1 Patient included in the study (Visone et al. (2011))
2 Patient recruited at Policlinico Gemelli, Rome, Italy
- - LLC021 died in march 2018 (not CLL-related)
* - - CLL027 is the previous time point of 228 in Visone et al (2011)
*** - - CLL233 is the previous time point of 234 in Visone et al (2011)
**** - - LLC098 died in september 2018 (CLL-related)